Serum Amyloid A Level in Patients with Juvenile Idiopathic Arthritis
DOI:
https://doi.org/10.12970/2310-9874.2017.05.02Keywords:
Juvenile Idiopathic Arthritis, Serum Amyloid A, Acute phase reactants.Abstract
Background and Aim of the Work: JIA is the commonest rheumatic disease in childhood characterized by inflammatory arthritis lasting more than 6 weeks before the 16th birthday. In addition to routine ESR and CRP, there are other inflammatory biomarkers as SAA. It is one of the major acute phase reactants which was found to be elevated in inflammatory arthritis and a good indicator of disease activity.
This study assessed the value of SAA level in a cohort of patients with JIA.
Subjects and Methods: 45 JIA patients and 40 healthy controls were recruited from the outpatient clinic of Rheumatology and Rehabilitation Department at MUCH. All patients underwent a thorough clinical evaluation. Assessment of JIA patients involved assessment of disease activity, tenderness and functional status. Laboratory tests were done including: CBC, ESR, CRP and SAA.
Results: A significant rise in SAA levels was found in JIA patients compared to control group and it was significantly higher in SJIA subtype. SAA level was positively correlated with JADAS-27, VAS, physician global assessment, C-HAQ, Ritchie articular index score, platelet count and ESR in 1st hour and 2nd hour. The levels of SAA were significantly lower in JIA patients taking methotrexate while it was significantly higher in cyclosporine treated patients.
Conclusion: SAA can be used as additional indicator of JIA disease activity. Moreover, it can help in differentiation between subtypes when combined with clinical features of the disease and it may be considered in assessment of patient, s response to therapy.
References
Huang JL. New advances in juvenile idiopathic arthritis. Chang Gung Med J 2012; 35: 1-14. https://doi.org/10.4103/2319-4170.106171
Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis. J Rheumatology 2004; 31: 390-2.
Beresford MW, Baildam EM. New advances in the management of juvenile idiopathic arthritis: non-biological therapy. Arch Dis Child Educ Pract Ed 2009; 94: 144-50. https://doi.org/10.1136/adc.2008.144576
Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501-23. https://doi.org/10.1046/j.1432-1327.1999.00657.x
Cunnane G, Grehan S, Geoghegan S, et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 2000; 27: 58-63.
Consolaro A, Ruperto N, Bazso A. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Care and Research 2009; 61: 658-66. https://doi.org/10.1002/art.24516
Falcone A, Cassone R, Rossi E, et al. Inter-observer agreement of the physician’s global assessment of disease activity in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2005; 23: 113-6.
Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 37: 393- 406.
Tennant A, Kearns S, Turner F, et al. Measuring the function of children with juvenile arthritis. Rheumatology (Oxford) 2001; 40: 1274-8. https://doi.org/10.1093/rheumatology/40.11.1274
Westergren A. Diagnostic tests: the erythrocyte sedimentation rate range and limitations of the technique. Triangle 1957; 3: 20-5.
Kind CJ, Pepys MB. The role of serum C-reactive protein (CRP) measurement in clinical practice. Int Med 1984; 5: 112-151.
Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009; 66: 9-26. https://doi.org/10.1007/s00018-008-8321-x
Vlam KD. Soluble and Tissue Biomarkers in Ankylosing Spondylitis. Best Practice & Research Clinical Rheumatology 2010; 24: 671-82. https://doi.org/10.1016/j.berh.2010.05.009
Nandi M, Ganguli SK, Mondal R, et al. Clinico-serological profile of juvenile idiopathic arthritis. Indian Pediatr 2009; 46: 640-1.
Nazi S, Mushtaq A, Rahman S, et al. Juvenile Rheumatoid Arthritis. Journal of the College of Physicians and Surgeons Pakistan 2013; 23: 409-12.
Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 2002; 29: 1520-30.
Quartier P, Prieurr AM. Juvenile idiopathic arthritis. Clinical aspects. Rev Prat 2007; 57: 1171-8.
Cantarini L, Giani T, Fioravanti A, et al. Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis. Yonsei Med J 2012; 53: 1045-8. https://doi.org/10.3349/ymj.2012.53.5.1045
Amar HA, Elhewala AA. Serum amyloid A in patients with juvenile idiopathic arthritis and its association with disease activity. International Journal of Advanced Research 2015; 3: 1246-54.
Salah S, Hamshary A, Lotfy H, et al. Juvenile Idiopathic Arthritis, the Egyptian Experience. Journal of Medical Sciences 2009; 9: 98-102. https://doi.org/10.3923/jms.2009.98.102
Galeotti L, Adrian K, Berg S, et al. Circulating survivin indicates severe course of juvenile idiopathic arthritis. Clinical and Experimental Rheumatology 2008; 26: 373-78.
Takako M, David E, Bonnie L, et al. Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus non response to therapy. Arthritis Research Therapy 2005; 7: 746-55. https://doi.org/10.1186/ar1723
Kutulculer NK, Neslihan EA, Elif A, et al. Immunoglobulin light chain levels can be used to determine disease stage in children with juvenile idiopathic arthritis Date. Clin Lab Sci 2011; 24: 93-8.
De Benedetti F, Massa M, Robbioni P. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34: 1158-63. https://doi.org/10.1002/art.1780340912
Velat Ş, Buğra Y, Aydın E, et al. Evaluation of the Mean Platelet Volume in Children with Juvenile Idiopathic Arthritis 1. Eur J Gen Med 2014; 11: 262-7. https://doi.org/10.15197/sabad.1.11.83
Schmitt-Sody M, Metz P, Gottschalk O. Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets 2007; 18: 365- 72. https://doi.org/10.1080/09537100701191315
Metes ID, Chew DW, patel AM, et al. Anti-tumor necrosis factor α therapy (etanercept) plus methotrexate lowers serum amyloid a levels to a greater extent than triple oral disease modifying drug anti-rheumatic therapy in early rheumatoid arthritis subjects. Arthritis & Rheumatism 2013; 65: 25-30.
Juan EL, Maria RM, Fernando MR, et al. Effect of cyclosporin A on inflammatory cytokine production by U937 monocyte like cells. Mediators of Inflammation 2000; 9: 169-74. https://doi.org/10.1080/09629350020008682
